U.S. UREA CYCLE DISORDERS TREATMENT MARKET ANALYSIS

U.S. Urea Cycle Disorders Treatment Market, By Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others), By Enzyme Deficiency Type (OTC – Ornithine Transcarbamylase, AS – Argininosuccinate Synthetase (citrullinemia), AG – Arginase, AL – Argininosuccinate Lyase, CPS1 – Carbamoyl Phosphate Synthase and NAGS – N-acetylglutamate Synthase), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)-

Published In : Mar 2023
Code : CMI5594
Pages :155
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Size and Trends

U.S. Urea Cycle Disorders Treatment market is estimated to be valued at US$ 510.0 million in 2023 and is expected to exhibit a CAGR of 3.56% during the forecast period (2023-2030). Increasing product approvals for urea cycle disorders and increasing number of pipeline products is expected to boost the growth of the market over the forecast period. Moreover, increasing adoption of inorganic growth strategies by key players for Urea Cycle Disorders Treatment by regulatory bodies is expected to propel the growth of the U.S. Urea Cycle Disorders Treatment market over the forecast period

U.S. Urea Cycle Disorders Treatment Market Report Snapshots